These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28231806)

  • 1. Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.
    Burmakin M; van Wieringen T; Olsson PO; Stuhr L; Åhgren A; Heldin CH; Reed RK; Rubin K; Hellberg C
    J Transl Med; 2017 Feb; 15(1):47. PubMed ID: 28231806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma.
    Olsson PO; Gustafsson R; In 't Zandt R; Friman T; Maccarana M; Tykesson E; Oldberg Å; Rubin K; Kalamajski S
    Mol Cancer Ther; 2016 Oct; 15(10):2455-2464. PubMed ID: 27474147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of integrin α
    Olof Olsson P; Gustafsson R; Salnikov AV; Göthe M; Zeller KS; Friman T; Baldetorp B; Koopman LA; Weinreb PH; Violette SM; Kalamajski S; Heldin NE; Rubin K
    Cell Commun Signal; 2018 Jul; 16(1):36. PubMed ID: 29966518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
    Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
    Pietras K; Ostman A; Sjöquist M; Buchdunger E; Reed RK; Heldin CH; Rubin K
    Cancer Res; 2001 Apr; 61(7):2929-34. PubMed ID: 11306470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
    Kłosowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
    PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
    Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
    Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors.
    Boucher Y; Lee I; Jain RK
    Microvasc Res; 1995 Sep; 50(2):175-82. PubMed ID: 8538498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
    Kitadai Y; Sasaki T; Kuwai T; Nakamura T; Bucana CD; Fidler IJ
    Am J Pathol; 2006 Dec; 169(6):2054-65. PubMed ID: 17148668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
    Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
    J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
    Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico investigations of intratumoral heterogeneous interstitial fluid pressure.
    Waldeland JO; Gaustad JV; Rofstad EK; Evje S
    J Theor Biol; 2021 Oct; 526():110787. PubMed ID: 34087266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
    Moawad EY
    J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
    Griffon-Etienne G; Boucher Y; Brekken C; Suit HD; Jain RK
    Cancer Res; 1999 Aug; 59(15):3776-82. PubMed ID: 10446995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
    Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
    Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
    Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibromodulin deficiency reduces collagen structural network but not glycosaminoglycan content in a syngeneic model of colon carcinoma.
    Olsson PO; Kalamajski S; Maccarana M; Oldberg Å; Rubin K
    PLoS One; 2017; 12(8):e0182973. PubMed ID: 28827814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphology/Interstitial Fluid Pressure-Tunable Nanopomegranate Designed by Alteration of Membrane Fluidity under Tumor Enzyme and PEGylation.
    Wu C; Wang Z; Wang X; Zou J; Wu Z; Liu J; Zhang W
    Mol Pharm; 2021 May; 18(5):2039-2052. PubMed ID: 33769816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.